Nurix Therapeutics, INC Form 4 insider transactions

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposition of common stock and restricted stock units to cover tax obligations.

Director Lori Anne Kunkel reported the disposition of 54,027 shares of Nurix Therapeutics common stock on July 17, 2024.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares of common stock on July 1, 2024, according to a Form 4 filing with the SEC.

Hans van Houte, CFO of Nurix Therapeutics, sold 20,000 shares of common stock at an average price of $20.0108 on June 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the sale of 1,864 shares of common stock on June 13, 2024, while also exercising options to acquire the same number of shares.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the exercise of stock options and subsequent sale of shares under a pre-arranged trading plan.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, exercised stock options and sold shares on June 3, 2024, according to a Form 4 filing with the SEC.

Director Paul M. Silva acquired 25,000 stock options in Nurix Therapeutics on May 20, 2024, vesting fully by May 20, 2025, subject to continued service.

Director Lori Anne Kunkel acquired 25,000 stock options in Nurix Therapeutics, Inc. on May 20, 2024.

Director Julia P. Gregory reports the acquisition of stock options in Nurix Therapeutics.

David L. Lacey, a director of Nurix Therapeutics, acquired 25,000 stock options on May 20, 2024, exercisable at $16.19.

Director Judith A. Reinsdorf of Nurix Therapeutics, Inc. was granted stock options to purchase 25,000 shares of common stock on May 20, 2024.

Director Edward C. Saltzman of Nurix Therapeutics, Inc. was granted stock options to purchase 25,000 shares of common stock on May 20, 2024.

Hans van Houte, CFO of Nurix Therapeutics, sold 3,499 shares of common stock at an average price of $12.826 per share on May 2, 2024, under a pre-arranged 10b5-1 trading plan.

Hans van Houte, CFO of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.